Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab + Chemotherapy in Adult Relapsed/Refractory CD22+ B-ALL (CHEPRALL)
NCT01219816Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Nov 2010
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of epratuzumab in acute lymphoblastic leukemia (ALL), sponsored by CHU de Nantes. Started Nov 2010; status: completed.
02
Drugs
epratuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01219816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01219816.